Provided by Tiger Fintech (Singapore) Pte. Ltd.

Elevation Oncology, Inc.

0.3344
-0.0156-4.46%
Post-market: 0.33860.0042+1.26%19:26 EDT
Volume:855.94K
Turnover:287.94K
Market Cap:19.80M
PE:-0.43
High:0.3600
Open:0.3500
Low:0.3300
Close:0.3500
Loading ...

Elevation Oncology Inc : Piper Sandler Cuts to Neutral From Overweight; Cuts Target Price to $0.70 From $10

THOMSON REUTERS
·
21 Mar

Elevation Oncology Inc : Wedbush Cuts to Neutral From Outperform; Cuts Target Price to $1.60 From $5

THOMSON REUTERS
·
21 Mar

Strategic Shift and Promising Developments Drive Buy Rating for Elevation Oncology

TIPRANKS
·
21 Mar

BUZZ-U.S. STOCKS ON THE MOVE-KKR, Micron Technology, Eli Lilly

Reuters
·
20 Mar

Elevation Oncology Shares Down 45% After Co Halts Development of Cancer Drug

THOMSON REUTERS
·
20 Mar

Sector Update: Health Care Stocks Decline Pre-Bell Thursday

MT Newswires Live
·
20 Mar

BUZZ-Elevation Oncology tumbles after halting development of cancer drug

Reuters
·
20 Mar

Elevation Oncology Drops Potential Metastatic Cancer Drug, Evaluates Strategic Options; Shares Fall Pre-Bell

MT Newswires Live
·
20 Mar

Elevation Oncology Restructures Amid EO-3021 Discontinuation

TIPRANKS
·
20 Mar

Elevation Oncology Shares Halt on Lay Offs, Discontinued Drug Candidate

Dow Jones
·
20 Mar

Elevation Oncology: as Part of Reduction, Chief Medical Officer, Valerie Malyvanh Jansento Step Down

THOMSON REUTERS
·
20 Mar

Elevation Oncology Inc - to Reduce Workforce by 70%

THOMSON REUTERS
·
20 Mar

Elevation Oncology to Discontinue Development of Eo-3021; Advancing Eo-1022, While Evaluating Strategic Options

THOMSON REUTERS
·
20 Mar

Elevation Oncology Inc - Continuing to Advance Potentially Differentiated Her3 ADC, Eo-1022

THOMSON REUTERS
·
20 Mar

Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options

PR Newswire
·
20 Mar

Elevation Oncology Shares Halted for News Pending Premarket

THOMSON REUTERS
·
20 Mar

Elevation Oncology Price Target Maintained With a $7.00/Share by Citizens Capital Markets

Dow Jones
·
10 Mar

Elevation Oncology Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Mar

Elevation Oncology’s Future in Jeopardy: Financing Challenges Threaten Product Development

TIPRANKS
·
08 Mar

Elevation Oncology Reports 2024 Financial Results and Progress

TIPRANKS
·
08 Mar